A Phase Il of a Therapeutic, Recombinant, Biologically Active HIV-1 Tat Protein Vaccine in HIV-Infected, Anti-Tat Negative, ARV-Treated Adult Volunteers
Clinical trial NCT01513135 · COMPLETED
Trial details
- NCT number
- NCT01513135
- Sponsor
- Barbara Ensoli, MD
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-03-01
- Primary completion
- 2014-05-01
- Enrollment
- 200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.